Perceptive Advisors LLC raised its stake in Zogenix, Inc. (NASDAQ:ZGNX) by 8.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,970,357 shares of the company’s stock after acquiring an additional 300,000 shares during the quarter. Zogenix makes up approximately 5.3% of Perceptive Advisors LLC’s investment portfolio, making the stock its 5th largest position. Perceptive Advisors LLC owned approximately 11.59% of Zogenix worth $160,799,000 at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. Cubist Systematic Strategies LLC acquired a new position in Zogenix in the third quarter valued at approximately $226,000. Sterling Capital Management LLC acquired a new position in shares of Zogenix during the 3rd quarter worth approximately $237,000. Teacher Retirement System of Texas acquired a new position in shares of Zogenix during the 4th quarter worth approximately $409,000. Guggenheim Capital LLC raised its stake in shares of Zogenix by 71.2% during the 4th quarter. Guggenheim Capital LLC now owns 12,843 shares of the company’s stock worth $514,000 after buying an additional 5,342 shares during the period. Finally, Voya Investment Management LLC raised its stake in shares of Zogenix by 13.5% during the 2nd quarter. Voya Investment Management LLC now owns 14,147 shares of the company’s stock worth $205,000 after buying an additional 1,686 shares during the period.
In other news, EVP Bradley S. Galer acquired 1,346 shares of Zogenix stock in a transaction that occurred on Wednesday, December 13th. The stock was purchased at an average cost of $36.59 per share, with a total value of $49,250.14. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 6.60% of the stock is currently owned by corporate insiders.
Zogenix (NASDAQ:ZGNX) last posted its quarterly earnings data on Tuesday, March 6th. The company reported ($1.14) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by ($0.17). Zogenix had a negative net margin of 309.76% and a negative return on equity of 81.65%. During the same period last year, the company earned ($0.95) earnings per share. research analysts anticipate that Zogenix, Inc. will post -3.12 EPS for the current year.
Several research analysts have recently weighed in on ZGNX shares. BidaskClub raised Zogenix from a “hold” rating to a “buy” rating in a research note on Friday, December 29th. Leerink Swann upped their target price on Zogenix from $50.00 to $54.00 and gave the stock an “outperform” rating in a research note on Friday, February 23rd. Mizuho reaffirmed a “buy” rating and set a $51.00 target price on shares of Zogenix in a research note on Thursday, February 1st. Zacks Investment Research raised Zogenix from a “sell” rating to a “hold” rating in a research note on Saturday, January 27th. Finally, ValuEngine raised Zogenix from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Zogenix currently has an average rating of “Buy” and a consensus price target of $46.40.
COPYRIGHT VIOLATION WARNING: “Perceptive Advisors LLC Has $160.80 Million Holdings in Zogenix, Inc. (ZGNX)” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2018/03/12/perceptive-advisors-llc-has-160-80-million-holdings-in-zogenix-inc-zgnx.html.
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.